Skip to main content
Log in

Heavily pretreated patient with nodal marginal zone lymphoma successfully treated with mosunetuzumab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Tapia-Galisteo A, Álvarez-Vallina L, Sanz L (2023) Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol 16(1):83. https://doi.org/10.1186/s13045-023-01482-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Shouse G (2023) Update on bi-specific monoclonal antibodies for blood cancers. Curr Opin Oncol 35(5):441–445. https://doi.org/10.1097/cco.0000000000000966

    Article  CAS  PubMed  Google Scholar 

  3. Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin JR, Lossos IS, Munoz J, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U (2023) Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. https://doi.org/10.1182/bloodadvances.2023010840

  4. Lynch RC, Poh C, Shadman M, Till BG, Smith SD, Ujjani C, Ottemiller S, Verni K, Fessel M, Joy B, Gausman D, Rasmussen H, Vandermeer J, Voutsinas J, Gopal AK (2023) Response-adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis. Hematol Oncol 41(S2):577–578. https://doi.org/10.1002/hon.3164_432

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marko Lucijanic.

Ethics declarations

Ethical approval

Treatment was approved by the Institutional Review Board. All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Consent to particicpate

Patient provided written informed consent for case presentation.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lucijanic, M., Sabljic, A., Vlasac Glasnovic, J. et al. Heavily pretreated patient with nodal marginal zone lymphoma successfully treated with mosunetuzumab. Ann Hematol 103, 1015–1016 (2024). https://doi.org/10.1007/s00277-023-05565-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05565-z

Navigation